Zacks Investment Research upgraded shares of Hill-Rom (NYSE:HRC) from a hold rating to a buy rating in a report published on Thursday morning. They currently have $96.00 price objective on the medical technology company’s stock.
According to Zacks, “Hill-Rom has outperformed the broader industry in the past year. Of late, the company has been seeing solid year-over-year increase in revenues on strong international growth primarily banking on the 'One Hill-Rom' approach. The company is focusing on product innovation, the latest one being Connex Cardio ECG. Hill-Rom has updated its 2020 long-range financial objectives and outlook considering gains from the new tax reform. Hill-Rom now expects to drive adjusted earnings by 12-14% on a compound annual basis through 2020, compared with the previous guidance of 10-12%. Moreover, an improvement in gross and adjusted operating margin buoys optimism.However, a decline in revenues at the Patient Support Systems segment is quite disappointing. Also, foreign exchange and a tough competitive landscape remain headwinds.”
HRC has been the topic of a number of other reports. Raymond James Financial raised shares of Hill-Rom from a market perform rating to an outperform rating and set a $94.00 price target on the stock in a research note on Wednesday, January 3rd. Needham & Company LLC reissued a buy rating on shares of Hill-Rom in a research note on Friday, January 26th. Goldman Sachs assumed coverage on shares of Hill-Rom in a research note on Wednesday. They issued a neutral rating and a $85.00 price target on the stock. ValuEngine raised shares of Hill-Rom from a hold rating to a buy rating in a research note on Friday, March 2nd. Finally, KeyCorp reissued a buy rating and issued a $97.00 price target on shares of Hill-Rom in a research note on Thursday, January 18th. Six investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. The stock has a consensus rating of Buy and an average price target of $93.89.
Hill-Rom (NYSE:HRC) last released its quarterly earnings results on Friday, January 26th. The medical technology company reported $0.92 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.79 by $0.13. The business had revenue of $669.70 million for the quarter, compared to the consensus estimate of $670.00 million. Hill-Rom had a net margin of 7.14% and a return on equity of 20.24%. The business’s revenue was up 5.1% on a year-over-year basis. During the same period in the previous year, the firm earned $0.75 EPS. equities analysts expect that Hill-Rom will post 4.62 earnings per share for the current year.
The firm also recently announced a quarterly dividend, which was paid on Friday, March 30th. Investors of record on Friday, March 23rd were paid a dividend of $0.20 per share. This is an increase from Hill-Rom’s previous quarterly dividend of $0.18. This represents a $0.80 annualized dividend and a yield of 0.95%. The ex-dividend date of this dividend was Thursday, March 22nd. Hill-Rom’s dividend payout ratio is presently 20.73%.
A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Amalgamated Bank increased its stake in Hill-Rom by 5.6% during the 4th quarter. Amalgamated Bank now owns 13,796 shares of the medical technology company’s stock worth $1,163,000 after buying an additional 729 shares during the period. Liberty Mutual Group Asset Management Inc. increased its stake in Hill-Rom by 5.4% during the 4th quarter. Liberty Mutual Group Asset Management Inc. now owns 16,724 shares of the medical technology company’s stock worth $1,410,000 after buying an additional 853 shares during the period. Commonwealth of Pennsylvania Public School Empls Retrmt SYS increased its stake in Hill-Rom by 10.0% during the 3rd quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 9,611 shares of the medical technology company’s stock worth $711,000 after buying an additional 877 shares during the period. LPL Financial LLC increased its stake in Hill-Rom by 27.0% during the 4th quarter. LPL Financial LLC now owns 4,660 shares of the medical technology company’s stock worth $394,000 after buying an additional 991 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank increased its stake in Hill-Rom by 52.5% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,357 shares of the medical technology company’s stock worth $283,000 after buying an additional 1,156 shares during the period. 82.50% of the stock is currently owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION WARNING: This article was first reported by Ticker Report and is the property of of Ticker Report. If you are viewing this article on another site, it was copied illegally and reposted in violation of US & international copyright & trademark laws. The correct version of this article can be viewed at https://www.tickerreport.com/banking-finance/3336050/hill-rom-hrc-upgraded-to-buy-by-zacks-investment-research.html.
Hill-Rom Company Profile
Hill-Rom Holdings, Inc is a global medical technology company. The Company partners with health care providers across care settings, by focusing on patient care solutions that improve clinical and economic outcomes in five core areas: advancing mobility, wound care and prevention, patient monitoring and diagnostics, surgical safety and efficiency and respiratory health.
Receive News & Ratings for Hill-Rom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hill-Rom and related companies with MarketBeat.com's FREE daily email newsletter.